Nuvectis Pharma, Inc. · NASDAQ:NVCT
Nuvectis Pharma — Investor Presentation (October 2026)
24 slides from Nuvectis Pharma's investor presentation, October 2026
Slide 1: Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. (NASDAQ: NVCT) Precision Medicine for the Treatment of Complement Related Diseases and Cancer October 2026
Slide 2: Forward Looking Statements
Forward Looking Statements Nuvectis Pharma, Inc. This presentation contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in
Slide 3: About Nuvectis
About Nuvectis Management team with track record of success Global regulatory approvals (FDA, EMA and PMDA) in renal, anemia and oncology indications Shay Shemesh Chief Development & Operations Officer Jelmyto® (mitomycin) NuvectisPharma, Inc. 3
Slide 4: Transformative Licensing Agreement with Haisco in June 2026
Transformative Licensing Agreement with Haisco in June 2026 Well capitalized to execute a broad clinical plan THE PARTNER POTENTIAL BEST-IN- FINANCIAL HIGHLIGHTS Haisco Pharmaceutical Group CLASS, ADVANCED Completed $115M follow-on (China) CLINICAL-STAGE PIPELINE offering (July 2026) • ~50 marketed
Slide 5: Our Pipeline
Our Pipeline Precision medicine for the treatment of complement mediated diseases and cancer Ciprocopan (NXP100): Factor B NXP200: Paradox Breaker BRAF NXP900: SRC/YES1 kinase inhibitor for complement Inhibitor for cancer inhibitor for cancer related diseases • Paradox breaker, brain • Enrolling Pha
Slide 6: Ciprocopan (NXP100)
Ciprocopan (NXP100) Once Daily, Oral Factor B Inhibitor for the Treatment of Complement Related Diseases
Slide 7: Ciprocopan (NXP100): Convenient, Once-Daily Oral Factor B Inhibitor
Ciprocopan (NXP100): Convenient, Once-Daily Oral Factor B Inhibitor Potential best-in-class complement Factor B inhibitor (CFBi) Clinical and regulatory validation in PNH 1× Convenient, once-daily oral administration • China approval in treatment-naïve patients • Previously treated PNH indication ap
Slide 8: Ciprocopan/NXP100: Factor B Becoming a Paramount Target in PNH
Ciprocopan/NXP100: Factor B Becoming a Paramount Target in PNH PNH is currently a ~$4.7B market, projected to grow to ~$7.4B by 2030 a Treatment is gradually shifting toward Factor B inhibition (oral, better efficacy) 1ST GENERATION 2ND G ENERATION NEXT GENERATION CFBI C5 Inhibitors Complement Facto
Slide 9: Ciprocopan's First Global Approval (China): Treatment Naive PNH
Ciprocopan’s First Global Approval (China): Treatment Naive PNH Demonstrated superiority vs Soliris (eculizumab, injectable C5 inhibitor class) Treatment Period Topline Phase 3 Results 24 weeks Ciprocopan* Eculizumab 200mg QD Randomized 1:1 Ciprocopan* 200mg QD （N=36） （N=37） Proportion of patients a
Slide 10: Ciprocopan's 2nd Marketing Application in China
Ciprocopan’s 2nd Marketing Application in China Previously-treated PNH - Patients with persistent anemia despite treatment with anti-C5 Treatment Period 24 weeks Primary Endpoint Ciprocopan* (N=36) Ciprocopan* 200 mg QD Proportion of patients 19/36 (52.8%) achieving Hgb >12 g/dL (35.5, 69.6) Primary
Slide 11: Ciprocopan (NXP100) Has Best In Class Potential in IgAN
Ciprocopan (NXP100) Has Best In Class Potential in IgAN Phase 2 data efficacy positions ciprocopan potentially in line with APRIL/BAFF inhibitors (all injectables) Parameter Week 4 Week 12 Week 24 Reduction in 24h-UPCR* relative to baseline vs. -45.3% -33% -57.7% placebo (Primary Endpoint) Change fr
Slide 12: Competitive Landscape in PNH
Competitive Landscape in PNH FDA Approved therapies – Factor B’s Expected to Become Leading Class Condition Drug Name MoA Dosing Administration Fabhalta Factor B Inhibitor Oral capsule twice daily Soliris C5 inhibitor IV infusion every 2 weeks PNH Ultomiris C5 inhibitor IV infusion every 8 weeks Emp
Slide 13: Complement Factor B FDA Approvals and Ongoing Clinical Trials
Complement Factor B FDA Approvals and Ongoing Clinical Trials Est. US addressable Fabhalta approvals and Indication Ciprocopan (Status) patient population ongoing clinical trials PNH - Naive ● Treatment naïve (China) APPROVALS ~5,500 ● PNH - Experienced ● Approval pending (China) IgAN ~200,000 ● ● P
Slide 14: NXP200
NXP200 A Paradox-Breaker BRAF Inhibitor for the Treatment of Cancer
Slide 15: BRAF in Cancer
BRAF in Cancer THE BRAF MUTATION FIRST GENERATION BRAF WHY IT MATTERS FOR NXP200 • Class 1: mutations in codon 600 INHIBITORS • NXP200 is a paradox-breaking, (most commonly V600E), active • Can target only Class 1 BRAF inhibitor designed to single monomers, RAS mutations block the pathway without in
Slide 16: NXP200: A Large Next-Generation BRAF Opportunity
NXP200: A Large Next-Generation BRAF Opportunity Oral, brain-penetrant, paradox-breaker BRAF inhibitor with potential best-in-class properties MARKET TODAY MARKET POTENTIAL BENCHMARK DEAL $5BN $12BN $2.5BN First-generation BRAF inhibitors With next-generation paradox- Servier’s April 2026 acquisitio
Slide 17: NXP200: Paradox Breaker BRAFi
NXP200: Paradox Breaker BRAFi Clinical proof of concept: Single agent responses in heavily pre-treated patients Free Base (Old) Formulation • Treatment with NXP200 resulted in ORR of 37% (7/19) Preliminary Efficacy Data – Phase I dose escalation (all pts. Previously treated with recurrent metastatic
Slide 18: NXP200: New Salt Form
NXP200: New Salt Form Clinical proof of concept (pilot study): single agent responses in heavily pre-treated patients Preliminary Single Agent Efficacy Data New Salt form enhances NXP200 systemic exposure (all pts. previously treated with recurrent metastatic disease) Cancer Type # of (V600X Patient
Slide 19: NXP900
NXP900 A SRC/YES1 Kinase Inhibitor for the treatment of Cancer
Slide 20: NXP900 Phase 1b Ongoing
NXP900 Phase 1b Ongoing Highly selective, unique mechanism of action: Complete shut-down of the YES1/SRC pathways by inhibiting the catalytic and scaffolding properties #1: NSCLC: osimertinib combination - EGFR mutated, previous response to osimertinib - ongoing #2: NSCLC: lorlatinib combination - A
Slide 21: NXP900 Combination With RAS Inhibitors
NXP900 Combination With RAS Inhibitors SRC activation is involved in multiple pathways leading to acquired resistance to Ras inhibition** SRC, YES1 and YAP1 activation have been validated 1 preclinically as drivers of resistance to RAS inhibitors. NXP900 inhibits at low nanomolar concentrations SRC
Slide 22: Milestones and News Flow
( NuvectisPharma, Inc. Milestones and News Flow
Slide 23: Expected Near-Term News Flow & Catalysts
Expected Near-Term News Flow & Catalysts Program Potential Catalyst Estimated Timeline Approval (China) — treatment-naïve PNH ✓ July 2026 Approval (China) — previously-treated PNH Q4 2026 PNH Phase 3 data (China) presentations at ASH Dec 2026 Complement US IND submission H2 2026 IgAN Pivotal Phase 3
Slide 24: Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. (NASDAQ: NVCT) Precision Medicine for the Treatment of Complement Related Diseases and Cancer October 2026
Nuvectis Pharma — Investor Presentation (October 2026) on 6ix